In this MinuteCE, Drs. Jose Rubio and Sunny Tang examine the recurrent course of bipolar disorder, predictors of relapse, and the clinical burden of residual mood symptoms and cognitive impairment. They discuss limitations of current pharmacologic therapies and review dopaminergic and cholinergic neurocircuitry, with emphasis on M1 and M4 muscarinic receptors as potential therapeutic targets for mania, psychosis, and cognitive dysfunction. The discussion also examines ongoing phase 3 BALSAM-1 and BALSAM-2 trials of xanomeline-trospium for acute mania and mania with mixed features, as well as its potential role in the bipolar disorder treatment algorithm.
Exploring the Potential Role of Emerging Muscarinic Therapies in the Treatment of Bipolar Disorder
5
episodes
37m
Details
Presenters
Commercial Support
This activity is supported by an independent educational grant from Bristol Myers Squibb.
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative requires all faculty and planners to disclose financial relationships with ineligible companies. All relevant financial relationships have been reviewed and mitigated to ensure that the content is free from commercial bias.
The following faculty and planners have disclosed relevant financial relationships with ineligible companies in the past 24 months.
Faculty:
Jose M. Rubio, MD, PhD
Assistant Professor of Psychiatry
Feinstein Institutes for Medical Research
Zucker Hillside Hospital
Glen Oaks, NY
Advisor/Consultant: Bristol Myers Squibb, Janssen, Karuna, Teva
Royalties: UpToDate
Contracted Researcher: Alkermes, Neurocrine
Sunny X. Tang, MD
Assistant Professor of Psychiatry
Feinstein Institutes for Medical Research
Zucker Hillside Hospital
Glen Oaks, NY
Contracted Researcher: I’m Beside You, Inc.
Ownership Interest: North Shore Therapeutics, Psyrin Inc.
Advisor/Consultant: Cogntiv, Inc.
Reviewers/Planners/Authors:- Cindy Davidson has no relevant relationships to disclose.
- Parul Yadav, MD, has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Discuss relapse and incomplete remission in bipolar disorder (BD)
- Explain current BD mania and mixed episode therapies by efficacy, tolerability, and limitations of durability across symptom domains
- Apply cholinergic and muscarinic neurocircuit concepts to understand neural mechanisms of bipolar illness and evaluate emerging muscarinic treatment options for BD mania, mixed features, and cognition
Target Audience
This activity has been designed to meet the educational needs of advanced practice providers who specialize in psychiatry and family medicine as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare professionals involved in managing patients with bipolar disorder.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.50 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credit(s). Approval is valid until 09/18/27. PAs should claim only the credit commensurate with the extent of their participation in the activity. 
Global Learning Collaborative (GLC) designates this activity for a maximum of 0.50 contact hour(s)/0.05 CEUs of pharmacy continuing education credit.
The Universal Activity Number (UAN) for this program is JA0006235-0000-26-122-H01-P. This learning activity is knowledge-based. Upon successful completion of the activity, continuing education credit will be electronically submitted to the National Association of Boards of Pharmacy (NABP). Pharmacists with questions may contact NABP Customer Service at custserv@nabp.net.Provider(s)/Educational Partner(s)
Global Learning Collaborative (GLC) designs and executes continuing education rooted in evidence-based medicine, clinical need, knowledge gap analysis, and careful consideration of learner feedback. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. GLC’s methodology is founded on a commitment to continuing medical education and the innovative assessment of its effects on clinical practice. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
